Breaking News

Lilly to Acquire Armo BioSciences for $1.6B

Gains AM0010 being investigated in a Phase III trial in pancreatic cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly & Co. has entered an agreement to acquire ARMO BioSciences Inc. for approximately $1.6 billion in cash, expanding its portfolio of immuno-oncology therapies. The acquisition, subject to customary closing conditions, is expected to close 2Q18.   ARMO, based in Redwood City, CA is developing cancer treatments that harness the body’s immune system to fight tumors. Its lead candidate, AM0010 is being investigated in a pivotal Phase III trial in pancreatic cancer. According to Armo, A...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters